The present invention relates compounds of formula (I)
wherein A and R
1
are as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.
Disclosed herein are compounds of formula (I)
wherein Ring A and R
1
are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.
Continuous flow photochemistry as an enabling synthetic technology: synthesis of substituted-6(5H)-phenanthridinones for use as poly(ADP-ribose) polymerase inhibitors
作者:Y. Fang、G. K. Tranmer
DOI:10.1039/c5md00552c
日期:——
Methods utilizing continuous flow photochemistry, an enabling synthetic technology, have been developed for the generation of phenanthridinones via an intramolecular photochemical cyclization of 2-chlorobenzamides for the purposes of generating poly(ADP-ribose) polymerase inhibitors. Herein we report 16 examples of a single-step flow photocyclization which produces substituted phenanthridinones in
Ipso Substitution as a Route to Benzo[<i>c</i>]quinolizines and 4-Hydroxycoumarins
作者:Yannan Liu、Mark J. Kurth
DOI:10.1021/jo0161126
日期:2002.4.1
A convenient ipso substitution method for the preparation of benzo[c]quinolizine (2) and 4-hydroxy-3-(2'-pyridyl)coumarin (3) has been developed. The intramolecular nucleophilic substitution reaction of 3-oxo-2-(2'-pyridyl)-(2-halophenyl)propanoate (1) in refluxing xylenes gives initially benzo[c]quinolizine, while further heating results in the formation of 4-hydroxycoumarin. A mechanism has been
[EN] ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS<br/>[FR] UTILISATION D'ACIDES PHENYLACETIQUES SUBSTITUES PAR ALPHA-(ARYLOXY, ARYLAMINO, ARYLTHIO OU ARYLMETHYLE SUBSTITUE PAR TRIFLUOROMETHYLE)-TRIFLUOROMETHYLE ET DE LEURS DERIVES EN TANT QU'AGENTS ANTIDIABETIQUES
申请人:METABOLEX INC
公开号:WO2005080340A1
公开(公告)日:2005-09-01
Compounds having a formula (1) or a pharmaceutically acceptable salt or prodrug thereof, are provided, and are useful for the treatment of metabolic disorders.